GNTbm focuses on epigenetic regulation research, and is devoted to the development of new drugs on three main themes. The first is the co-development of licensed-in new drug Chidamide with international pharmaceutical company in new indication, the second is the in-house research and development of tumor microenvironment regulators and epigenetic immunomodulators for cancer immunotherapy, and the third is the in-house development of HDACs 1, 2, 3 protein proteolysis chimera degradation drugs.